SF 1. Heat map showing the tumor growth inhibition (TGI) of six metabolic inhibitors in PDX panel. ND denotes anti-tumor efficacy was not determined in respective PDX.

SF 2. Tumor growth curves of PDXs treated with phenformin. Tumor harboring animals were administered with vehicle (control) or phenformin as described in Materials and Methods. Error bars represent mean ± standard error of mean (SEM). **** p <0.0001, ** p <0.01, * p<0.05.

SF 3. Tumor doubling time of 12 individual PDXs. Tumor harboring animals were administered with vehicle (control) or phenformin as described in Materials and Methods. Error bars represent mean ± standard error of mean (SEM). Asterisk mark denotes statistically significant tumor doubling time compared to vehicle treatment..

SF 4. Aggregate tumor doubling time of PDXs treated with vehicle or phenformin.

A. PDXs with relatively higher baseline tumor growth rates showed better TGIs with phenformin treatment compared to PDXs with slower tumor growth rates. Aggregate baseline tumor doubling time (TDT) was 17.42 ± 1.993 days in 5 PDXs which showed non-significant TGI (P420, JH015, JH010, P374 and P215) to phenformin treatment. However, TDT was 12.77 ± 0.8833 days in the PDXs which showed statistically significant TGI (JH033, P265, P194, P410, P253, P281 and P198) to phenformin treatment. **B.** Aggregate tumor doubling time of all tumors of control and phenformin treatment in 12 PDXs. Phenformin treatment prolongs the tumor doubling time of PDXs. Error bars represent mean ± standard error of mean (SEM). Asterisk marks denotes statistical significance.